Display options
Cite
Chatel-Chaix L, Baril M, Lamarre D. Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010;2(8):1752-65doi: 10.3390/v2081752.
Chatel-Chaix, L., Baril, M., & Lamarre, D. (2010). Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses, 2(8), 1752-65. https://doi.org/10.3390/v2081752
Chatel-Chaix, Laurent, et al. "Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel." Viruses vol. 2,8 (2010): 1752-65. doi: https://doi.org/10.3390/v2081752
Chatel-Chaix L, Baril M, Lamarre D. Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010 Aug;2(8):1752-65. doi: 10.3390/v2081752. Epub 2010 Aug 20. PMID: 21994705; PMCID: PMC3185733.
Copy Download .nbib Format: NLM
Share it on

Viruses. 2010 Aug;2(8):1752-65. doi: 10.3390/v2081752. Epub 2010 Aug 20.

Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel.

Viruses

Laurent Chatel-Chaix, Martin Baril, Daniel Lamarre

Affiliations

  1. Institut de Recherche en Immunologie et en Cancérologie (IRIC), Montréal, Québec, H3T 1J4, Canada; E-Mails: [email protected] (L.C.-C.); [email protected] (M.B.).

PMID: 21994705 PMCID: PMC3185733 DOI: 10.3390/v2081752

Abstract

Hepatitis C virus (HCV) infection is a serious and growing threat to human health. The current treatment provides limited efficacy and is poorly tolerated, highlighting the urgent medical need for novel therapeutics. The membrane-targeted NS3 protein in complex with the NS4A comprises a serine protease domain (NS3/4A protease) that is essential for viral polyprotein maturation and contributes to the evasion of the host innate antiviral immunity by HCV. Therefore, the NS3/4A protease represents an attractive target for drug discovery, which is tied in with the challenge to develop selective small-molecule inhibitors. A rational drug design approach, based on the discovery of N-terminus product inhibition, led to the identification of potent and orally bioavailable NS3 inhibitors that target the highly conserved protease active site. This review summarizes the NS3 protease inhibitors currently challenged in clinical trials as one of the most promising antiviral drug class, and possibly among the first anti-HCV agents to be approved for the treatment of HCV infection.

Keywords: HCV; HCV replicon; NS3 protease; antiviral therapy; clinical trial; protease inhibitor

References

  1. Hepatology. 2010 Aug;52(2):421-9 - PubMed
  2. Nat Genet. 2009 Oct;41(10):1100-4 - PubMed
  3. Cell. 1996 Oct 18;87(2):331-42 - PubMed
  4. N Engl J Med. 2009 Apr 30;360(18):1839-50 - PubMed
  5. N Engl J Med. 2010 Apr 8;362(14):1292-303 - PubMed
  6. Nature. 2003 Nov 13;426(6963):186-9 - PubMed
  7. Cell. 1996 Oct 18;87(2):343-55 - PubMed
  8. J Virol. 2000 Feb;74(4):2046-51 - PubMed
  9. Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):6001-6 - PubMed
  10. N Engl J Med. 2009 Apr 30;360(18):1827-38 - PubMed
  11. J Biol Chem. 2008 Oct 31;283(44):29929-37 - PubMed
  12. J Med Chem. 2007 May 17;50(10):2310-8 - PubMed
  13. Ann Intern Med. 2004 Mar 2;140(5):346-55 - PubMed
  14. J Biol Chem. 2007 Nov 30;282(48):34913-20 - PubMed
  15. J Biol Chem. 2010 Jun 4;285(23):17821-32 - PubMed
  16. Annu Rev Immunol. 2007;25:71-99 - PubMed

Publication Types